Glenmark Pharma Launches Epinephrine Injection, Shares Fall

Leading company engaged in pharmaceuticals sector, Glenmark Pharmaceuticals Ltd today announced the launch Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial. Glenmark Pharmaceuticals share price slipped 0.45% in morning trade on Bombay Stock Exchange (BSE) to Rs 1310.40 per share. The company’s market capitalisation stood at Rs 36,942.66 crore.

The stock offers a return of equity of 25.38%. The stock outperformed market in last 1-year with impressive returns. The large cap pharma stock jumped 41.28% in last 1-year while BSE Sensex gained 2.07% and BSE Healthcare Index surged 9.75% during the same period. Check details below:

Glenmark Pharma Launches Epinephrine Injection USP, Shares Slip

Glenmark Pharma Announces Launch of Epinephrine Injection USP

According the exchange filing of the company issued today, “Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial. Glenmark’s Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL), of BPI Labs, LLC, NDA 205029. This launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.”

According to IQVIATM sales data for the 12-month period ending December 2024, the Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) market2 achieved annual sales of approximately $42.7 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”

Glenmark Pharmaceuticals Shares Performance

The 52-week high price of Glenmark Pharmaceuticals shares on BSE stood at Rs 1830.05 per share (as on 15/10/2024) and 52-week low price is Rs 883.50 per share, respectively. Glenmark Pharmaceuticals shares slipped 18.81% year-to-date (YTD), fell 13.98% in last 3-months, and declined 23.22% in last 6-months. The stock turned green in last 1-year with gain of over 41% and offered triple digit jump of 202.81% in last 2-years. In last 5-years, the stock offered eye-catching returns of 346.02%.

About

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.